Molecular Infectious Disease Testing Market

List of Tables

The Molecular Infectious Disease Testing Market is projected to grow by USD 19.34 billion at a CAGR of 10.77% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 9.44 billion
Estimated Year [2026]	USD 10.43 billion
Forecast Year [2032]	USD 19.34 billion
CAGR (%)	10.77%

Molecular Infectious Disease Testing: Executive Overview

Molecular infectious disease testing uses nucleic-acid technologies, including polymerase chain reaction and other amplification methods, to detect pathogens or pathogen-specific genetic material. Its clinical value is strongest where rapid, sensitive, and targeted diagnosis can guide treatment, infection-control decisions, surveillance, and public-health response. The field spans respiratory, gastrointestinal, sexually transmitted, blood-borne, healthcare-associated, and emerging infections across hospitals, laboratories, clinics, and decentralized care settings.

From Centralized Diagnosis to Connected, Decentralized Care

The landscape is shifting from centralized laboratory workflows toward integrated diagnostic networks that combine high-throughput platforms with near-patient and point-of-care testing. Multiplex panels can support differential diagnosis, while automation, connectivity, and standardized workflows improve operational consistency. Adoption is also shaped by antimicrobial-resistance surveillance, outbreak preparedness, laboratory capacity, reimbursement rules, procurement practices, and the need to maintain performance across varied specimen types and care environments.

Artificial Intelligence Strengthens Interpretation and Workflow Management

Artificial intelligence can contribute to molecular infectious disease testing through result interpretation, quality-control monitoring, anomaly detection, laboratory scheduling, and integration of test results with clinical and epidemiological information. Its practical impact depends on representative training data, transparent validation, cybersecurity, human oversight, and clear accountability for incorrect or uncertain outputs. AI is most useful when it augments qualified laboratory and clinical judgment rather than replacing analytical validation or established biosafety procedures.

Regional Insights: Uneven Capacity, Shared Preparedness Priorities

North America emphasizes rapid diagnostics, laboratory automation, antimicrobial-resistance monitoring, and integration with electronic health records. Europe combines strong laboratory networks with regulatory and cross-border data requirements. Asia-Pacific presents substantial diversity, ranging from advanced urban laboratory systems to settings where access, logistics, and workforce availability remain constraints. Latin America continues to prioritize decentralized access, surveillance, and dependable supply chains. The Middle East is strengthening specialized hospital and reference-laboratory capacity, while Africa focuses on expanding testing access, specimen transport, workforce capability, and outbreak-response infrastructure.

Group Insights: Trade, Regulation, and Security Shape Adoption

ASEAN markets commonly face differences in laboratory maturity, procurement systems, and regulatory alignment, making interoperability and regional preparedness important. BRICS members reflect varied public-health priorities and domestic manufacturing capabilities, with collaboration relevant to access and resilience. The European Union emphasizes harmonized regulation, surveillance, and cross-border health-data exchange. G7 countries generally prioritize advanced diagnostics, biosecurity, and innovation governance. GCC countries are strengthening centralized and hospital-based capacity, while NATO members place additional emphasis on health security, interoperability, and readiness for biological threats.

Country Insights: Diverse Priorities Across Major Testing Systems

Australia emphasizes geographically distributed access, surveillance, and laboratory quality; Brazil balances broad public-health needs with regional access challenges. Canada prioritizes networked public-health laboratories and remote-service delivery, while China continues expanding diagnostic capacity and digital health integration. France, Germany, Italy, Spain, and the United Kingdom focus on laboratory quality, antimicrobial resistance, preparedness, and coordinated healthcare delivery. India combines large-scale diagnostic demand with efforts to widen access and strengthen domestic capacity. Japan and South Korea emphasize automation, quality systems, and rapid response. Mexico continues to address uneven regional access and surveillance needs. Russia's priorities include national laboratory capability and infectious-disease monitoring. The United States focuses on advanced molecular workflows, decentralized testing, healthcare integration, and public-health preparedness.

Actions for Leaders: Build Resilient, Clinically Integrated Testing Networks

Industry leaders should align assay portfolios with clearly defined clinical and public-health use cases, validate performance across relevant populations and specimens, and design workflows for both centralized and decentralized settings. Investments should prioritize interoperability, cybersecurity, quality management, workforce training, supply-chain resilience, and transparent evidence generation. Organizations adopting AI should establish governance, monitor performance across demographic and geographic groups, preserve human review, and document model changes. Partnerships with laboratories, clinicians, public-health agencies, and procurement authorities can improve implementation and ensure that testing contributes to appropriate treatment and surveillance decisions.

Research Methodology: Evidence-Based Assessment of Molecular Testing Dynamics

This executive summary is structured around the supplied market definition and the required geographic and economic groupings. It synthesizes established, data-backed themes in molecular diagnostics, including technology development, laboratory operations, clinical utility, public-health surveillance, regulation, infrastructure, and digital integration. Regional, group, and country narratives are comparative and qualitative; they avoid market estimates, market shares, forecasts, and unsupported company-specific claims. Conclusions should be interpreted alongside current regulatory guidance, peer-reviewed evidence, laboratory standards, and jurisdiction-specific public-health data.

Conclusion: Reliable Molecular Testing Depends on Integration and Trust

Molecular infectious disease testing is becoming a core component of modern diagnosis, surveillance, and preparedness. Its benefits depend not only on assay sensitivity or platform speed, but also on appropriate clinical use, accessible infrastructure, validated workflows, skilled personnel, secure data exchange, and resilient supply chains. The strongest long-term strategies will connect laboratory innovation with public-health priorities while applying AI cautiously, maintaining scientific transparency, and preserving expert oversight.

Product Code: MRR-FF5E5BF3B455

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Molecular Infectious Disease Testing Market, by Product Type

7.1. Introduction
7.2. Instruments
7.3. Reagents & Kits
7.4. Software & Services

8. Molecular Infectious Disease Testing Market, by Technology

8.1. Introduction
8.2. DNA Microarrays
8.3. DNA Sequencing & Next-Generation Sequencing
8.4. In Situ Hybridization
8.5. Isothermal Nucleic Acid Amplification Technology
8.6. Polymerase Chain Reaction

9. Molecular Infectious Disease Testing Market, by Pathogen Type

9.1. Introduction
9.2. Bacterial
9.3. Fungal
9.4. Parasitic
9.5. Viral

10. Molecular Infectious Disease Testing Market, by Specimen Type

10.1. Introduction
10.2. Blood
10.3. Respiratory
10.4. Stool
10.5. Urine

11. Molecular Infectious Disease Testing Market, by Application

11.1. Introduction
11.2. Diagnostic Testing
11.3. Epidemiological Investigations
11.4. Screening Testing
11.5. Therapeutic Monitoring

12. Molecular Infectious Disease Testing Market, by End Users

12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Hospitals & Clinics
12.4. Research Institutes

13. Molecular Infectious Disease Testing Market, by Region

13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa

14. Molecular Infectious Disease Testing Market, by Group

14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO

15. Molecular Infectious Disease Testing Market, by Country

15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea

16. Competitive Landscape

16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
- 16.2.1. Concentration Ratio (CR)
- 16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Abbott Laboratories
17.2. Agilent Technologies, Inc.
17.3. Altona Diagnostics GmbH
17.4. Becton, Dickinson and Company
17.5. Bio-Rad Laboratories, Inc.
17.6. BioFire Diagnostics, LLC
17.7. bioMerieux SA
17.8. Cepheid by Danaher Corporation
17.9. Eurofins Viracor LLC
17.10. F. Hoffmann-La Roche Ltd
17.11. GenScript Biotech Corporation
17.12. Grifols S.A.
17.13. Hologic Inc.
17.14. Illumina, Inc.
17.15. Luminex Corporation
17.16. Merck KGaA
17.17. Myriad Genetics, Inc.
17.18. Novacyt Group
17.19. PerkinElmer, Inc.
17.20. Qiagen N.V.
17.21. QuidelOrtho Corporation
17.22. Seegene Inc.
17.23. Siemens Healthineers
17.24. Sysmex Corporation
17.25. Thermo Fisher Scientific, Inc.

18. Key Experts